Generated by AI
Corcept Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines that modulate cortisol activity to address serious endocrine, oncologic, metabolic, and neurologic disorders. Its commercial portfolio is centered on Korlym, an oral therapy used for adults with endogenous Cushing’s syndrome and related hypercortisolism. The company also advances a pipeline of selective cortisol modulators across multiple therapeutic areas, including relacorilant for Cushing’s syndrome and certain cancers, Lifyorli for oncology, and other investigational programs in metabolic disease and amyotrophic lateral sclerosis. Corcept Therapeutics serves the specialized rare-disease and specialty-pharmaceutical markets, where its products and research are aimed at conditions with limited treatment options. The company is headquartered in Redwood City, California.
Website101 Redwood Shores Parkway
Redwood City, CA, 94065
United States
The latest articles about CORT.
Corcept Therapeutics (CORT) just delivered a sharp jump in profitability in its third quarter report, with net income of US$126.78 million and diluted EPS of US$1.01 from continuing operations. That profit jump landed against a sharp reset in sentiment, with Corcept Therapeutics’ share price down 40.11% over the past month and 35.33% over 90 days, even after an 87.51% year-to-date share price gain and a 186.18% three-year total shareholder return that points to strong long-run backing for the...
Summary of Oct 26's posts. Generated by AI.
Summary of Oct 21's posts. Generated by AI.
Summary of Dec 31's posts. Generated by AI.
Summary of Oct 23's posts. Generated by AI.
Investors talking about CORT also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.